Cipla Acquires Inzpera Healthsciences for ₹110.65 Crore

Cipla Ltd has signed a definitive agreement to acquire 100% stake in Inzpera Healthsciences, a pediatric and wellness-focused pharma company, for ₹110.65 crore. This acquisition will strengthen Cipla’s presence in child health and nutrition segments, while leveraging its existing distribution reach.

The transaction is expected to close within one month, post regulatory clearances. With this acquisition, Cipla aims to expand its product basket in lifestyle and preventive healthcare — a key focus area for FY26–FY27 growth.

Pharma investors can track such developments alongside Nifty Option Intraday Tip momentum to capture opportunities in healthcare consolidations.

Hero MotoCorp Reports Festive Season Surge

Hero MotoCorp achieved nearly 10 lakh retail sales in October 2025, supported by strong festive demand. The company also crossed 6 lakh wholesale units for the second consecutive month. The EV segment, under the “VIDA” brand, posted 117% YoY growth in Vahan registrations — signaling accelerated adoption in the premium scooter category.

Global expansion into Europe and Latin America continues to add new revenue channels. The management expects FY26 to be a defining year for EV profitability.

Titan and 3M India Deliver Healthy Q2 Results

Titan Company posted 25% YoY revenue growth to ₹16,533 crore, with jewellery continuing as its largest contributor. However, EBITDA margin fell slightly to 9.8% due to higher gold prices and input costs. Despite this, the festive outlook remains strong, backed by double-digit store expansion across regions.

3M India delivered a net profit of ₹191 crore (+43% YoY), with revenue rising to ₹1,266 crore. Margin expansion to 20.2% reflects strong operating discipline. The company’s healthcare and consumer verticals led growth, with automotive and industrial adhesives showing steady improvement.

Consumer and diversified players like Titan and 3M remain solid portfolio holdings for investors aligned with Bank Nifty Option Intraday Tip trading strategies focused on defensive yet growth-oriented sectors.

Vedanta Guides for Record $6 Billion EBITDA in FY26

Vedanta Ltd surged 3% after guiding for record EBITDA of nearly $6 billion in FY26, supported by strong aluminium and zinc performance. The management reaffirmed plans for continued deleveraging and confirmed that the long-awaited demerger will likely be completed within FY26.

Brokerages turned optimistic, projecting that improving commodity prices and cost efficiencies could drive further rerating for the stock.

Investor Takeaway

Corporate India’s Q2 FY26 results highlight resilient demand and margin stability across consumer, industrial, and metal sectors. Hero MotoCorp’s festive success, Cipla’s acquisition, and Vedanta’s guidance indicate broad-based recovery momentum heading into H2 FY26.

Investors should stay tuned for further updates from midcaps and upcoming IPO listings as market liquidity remains robust.

Access premium insights and expert-reviewed strategies at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.